New futures contracts on leading U.S. companies offer active traders a more capital-efficient and flexible way to trade individual stocks

CHICAGO, July 27, 2026 /PRNewswire/ — NinjaTrader Group, a global leader in retail futures trading, today announced that CME Group Single Stock futures are live and immediately available for eligible users on the NinjaTrader platform. A major launch for the industry, these new CME Group contracts give active traders a way to trade individual stocks like Nvidia, Tesla, Apple and Amazon with the flexibility of futures.

This launch expands NinjaTrader’s equity index complex with the addition of CME Group Single Stock futures, giving traders the ability to express directional views on specific companies and well-known brands alongside the index products they already trade. CME Group’s initial launch will be a phased rollout across more than 50 top U.S. companies from the S&P 500, Nasdaq 100 and Russell 1000.

“Retail traders today are more active, informed, and focused on high-conviction opportunities than ever before and this launch of Single Stock futures from CME Group represents the next evolution of retail trading,” said Martin Franchi, CEO, NinjaTrader Group. “Creating direct access to market-moving companies like Nvidia, Tesla, Google and Apple with the speed, flexibility and capital efficiency of futures without the complexity of options, is a major advancement for the industry. We believe Single Stock futures will fundamentally reshape how individual investors trade and engage with volatility, earnings and real-time market events.”

“We are pleased to work with firms like NinjaTrader in expanding access to CME Group Single Stock futures,” said Tim McCourt, Global Head of Equities, FX and Alternative Products at CME Group. “Broader access to these centrally cleared, financially settled contracts brings the capital efficiencies and near 24/7 access of the futures market to leading U.S. stocks, providing investors with a highly transparent, regulated tool to manage their equity exposure.”

Single Stock futures give traders a new, streamlined way to gain tactical exposure to individual companies with less upfront capital than traditional stock purchases. Unlike options, Single Stock futures eliminate the need to manage Greeks, time decay and complex multi-leg chains, making it easier to express bullish or bearish views without stock borrowing requirements. Additionally, they offer the flexibility to respond to earnings reports, geopolitical developments, and overnight market events in real time, as they trade nearly 24 hours a day during the trading week. Designed for active futures, options and equity traders seeking simpler directional exposure, Single Stock futures reflect a broader industry shift toward products tied to real-time market movement and high-profile brands.

“Single Stock futures will open the door to an entirely new generation of active traders by bringing stock and options traders into the futures ecosystem through well-known, market-moving companies that are familiar, accessible and mainstream,” adds Franchi. “As retail traders become more sophisticated and event-driven, Single Stock futures have the potential to dramatically expand and reshape investor participation in futures trading.”

To start trading or learn more, visit ninjatrader.com.

About NinjaTrader Group
NinjaTrader Group is a global leader in retail futures and trading technology. Since 2003, NinjaTrader has been empowering a community of almost 3.9 million users with cutting-edge technology, ultra-low commissions and world-class support. Our modern, cloud-based platform, available on desktop, web and mobile, gives traders the freedom to seize market opportunities anytime, anywhere. NinjaTrader Clearing, LLC provides direct access to the futures markets, while NT Technologies delivers new tools, seamless NinjaTrader platform integration, and institutional-grade technology to support both individual prop traders and prop trading firms. For institutions, NinjaTrader Connect delivers a comprehensive suite of B2B solutions, providing advanced technology and financial infrastructure for technology providers. For more information, visit www.ninjatrader.com.

NinjaTrader Clearing, LLC offers security futures products. Futures and security futures trading involves substantial risk and is not suitable for everyone. Losses may exceed the initial investment. Past performance is not necessarily indicative of future results. View Risk Disclosure Statement for Security Futures Products.

NinjaTrader Clearing, LLC d/b/a NinjaTrader, Kraken Derivatives US, and Tradovate is a CFTC-registered futures commission merchant and an NFA Member (NFA ID: 0309379). View Disclosures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ninjatrader-to-offer-cme-group-single-stock-futures-giving-active-traders-direct-access-to-top-us-brands-including-nvidia-tesla-and-apple-302834810.html

SOURCE NinjaTrader

As AI agents move deeper into regulated scientific workflows, AINGENS argues that autonomy must be bound by evidence, traceability, and human oversight before it can be trusted.

COLUMBIA, Md., July 27, 2026 /PRNewswire/ — OpenAI’s disclosure that its AI models broke out of a controlled security test, and compromised systems has turned a theoretical warning into a real-world governance failure. The models exploited a previously unknown vulnerability, gained internet access, and chained actions across multiple systems while pursuing a narrow testing goal. The incident illustrates the risk facing regulated scientific workflows as AI begins to act, not just write. Systems can now search literature, summarize evidence, draft claims, revise materials, and move content through multistep processes. Once that happens, the danger is no longer limited to an inaccurate answer. An agent can select the wrong source, take unintended action, or advance scientific content without sufficient human review.

“Uncontrolled, unmonitored, and unverified agent use is becoming a serious risk in life sciences,” said Ome Ogbru, PharmD, founder and CEO of AINGENS, a life sciences AI company focused on governed scientific workflows. “An agent can assist with the work, but it cannot decide if the work is good enough, and it cannot own the human accountability behind it.”

AI Risk Is Moving from Wrong Answers to Wrong Actions

Adoption is moving faster than governance across many life science organizations. Recent NVIDIA survey of healthcare and life sciences organizations illustrates how quickly adoption is accelerating:

70% of respondents were actively using AI models.69% were using generative AI and large language models.47% were already using or assessing AI agents.

In pharmaceutical and biotechnology organizations, the leading reported agentic AI use cases were in literature review and data analysis.

McKinsey’s 2026 AI Trust Maturity Survey warned that organizations must account for systems taking unintended actions, misusing tools, or operating beyond proper guardrails. Only about 30% of surveyed organizations had reached higher maturity levels in strategy, governance and agentic AI controls, while nearly two-thirds cited security and risk concerns as the leading obstacle to scaling agentic AI.

“The word ‘agent’ can create the expectation that the system will deliver something ready to use,” Dr. Ogbru said. “But someone still has to define the task, select the evidence, validate the result, correct what is wrong, and approve what moves forward.”

Governance Must Be Built into the Scientific Workflow

Broad AI policies can establish organizational principles, but they cannot govern every scientific task in the same way. The controls required for literature retrieval may differ from those needed to draft a medical claim, create a presentation, or move approved content into another system.

Oversight should become stronger as the scientific, regulatory, clinical outcomes, and business consequences of a task increase. A formatting error can usually be corrected without affecting the substance of the work. A system that relies on outdated research, omits contradictory evidence, or applies the wrong data to a medical claim can create a far more serious problem, particularly if the material advances into external use before the mistake is identified.

Evidence-bound AI is one way to manage that risk. It requires users to define the knowledge the system should use rather than assuming it understands the scientific question, product, or organization. The system should remain within those sources, show what happened at each step, and indicate when the necessary data wasn’t provided. “If the evidence is not available, the system should be able to say, ‘I don’t have it,’ rather than reaching somewhere else for an answer,” Dr. Ogbru said.

Scientific AI Is More Than a Writing Tool

AINGENS developed the Medical Affairs Content Generator (MACg) to support regulated scientific and medical content workflows. The platform connects real-time PubMed search, literature summarization, evidence gathering, drafting, automatic citations, reference management, editing, collaboration, and presentation development inside one environment. MACg supports traceability and auditability of all outputs.

MACg includes agents that complete defined tasks based on user instructions, but it is not designed to operate as an autonomous decision-maker. Whether the work is ready to advance remains a decision for human experts, who must review the evidence trail and confirm that the required standards have been met. The platform supports the review and editing of generated content. The structure is intended to reduce manual work while preserving expert oversight over evidence choice, content generated, and final approval.

Scientific materials already require expert review, whether the first draft is produced manually or with AI assistance. The efficiency comes from reducing repetitive and laborious work at multiple steps in the workflow.

Mystery AI Is not an Option for Life Sciences Buyers

As scientific AI products multiply, life sciences organizations cannot evaluate them on model speed performance alone. They also need to know the source of the system’s evidence, whether it has been tested in the intended workflow, and whether its actions can be reconstructed when a claim, citation, or output is challenged. Just as important is how the system responds when evidence is incomplete, inappropriate, or outside its approved scope.

If a vendor does not reveal the AI models in their solution or cannot explain what is behind the product or show how an output was produced, the organization is being asked to accept risk it cannot measure. “‘Mystery AI’ should be a red flag for life sciences buyers,” Dr. Ogbru said. “In regulated scientific work, experts must be able to intervene, correct the record, and remain accountable for the outcomes. Evidence-bound AI is the right path forward.”

About AINGENS

AINGENS is a life sciences software company transforming how scientific and medical content is created in regulated healthcare environments. Founded by Ome Ogbru, PharmD, with more than 20 years of experience in pharma and biotech, the company combines deep life sciences expertise with advanced technologies to build integrated AI‑powered platforms that streamline some of the most time‑consuming steps in scientific, clinical, and medical workflows.

Its flagship platform, MACg (Medical Affairs Content Generator), is an end-to-end, evidence-based workspace that integrates real-time PubMed search, document-grounded reasoning, automated citation generation, drafting, slide generation and collaboration in a private, secure environment. By embedding traceability and source alignment directly into the workflow, AINGENS helps medical affairs and medical writing teams transform scientific evidence to publication and conference-ready content without compromising scientific rigor or regulatory integrity. Learn more at https://macg.ai.

References:

Asaftei, G. M., Roberts, R., Sticha, A., & Prinsen, C. (2026, March 25). State of AI trust in 2026: Shifting to the agentic era. McKinsey & Company. mckinsey.com/capabilities/tech-and-ai/our-insights/tech-forward/state-of-ai-trust-in-2026-shifting-to-the-agentic-eraCress, L. (2026, July 22). OpenAI says its AI went rogue and launched “unprecedented” cyber-attack. bbc.com/news/articles/c3ek3gvdnj3oGartner. (2026, May 26). Gartner says applying uniform governance across AI agents will lead to enterprise AI agent failure [Press release]. gartner.com/en/newsroom/press-releases/2026-05-26-gartner-says-applying-uniform-governance-across-ai-agents-will-lead-to-enterprise-ai-agent-failureNVIDIA. (2026). State of AI in healthcare and life sciences: 2026 trends [Survey report]. nvidia.com/content/dam/en-zz/Solutions/lp/survey-report/healthcare-state-of-ai-report-2026-4559650-web.pdf

Media Inquiries: 

Karla Jo Helms 

JOTO PR ™ 

727-777-4629 

Jotopr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/from-wrong-answers-to-wrong-actions-the-new-risk-of-agentic-ai-in-life-sciences-302834539.html

SOURCE AINGENS

Patent reflects Pilot’s continued investment in innovating charitable gaming

RENO, Nev., July 27, 2026 /PRNewswire/ — Pilot Gaming Systems, Inc. (“Pilot” or “Pilot Games”) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Pilot’s patent application covering its Standard Animated Roll-up for Electronic Pull-Tab Games. Once issued, the patent will become Pilot’s second recently issued U.S. patent protecting innovations in its electronic pull-tab gaming platform.

The newly-allowed patent builds upon Pilot’s ongoing commitment to developing original technology that enhances the player experience while supporting charitable organizations through engaging, state-of-the-art electronic gaming products.

“At Pilot, innovation has always been central to who we are,” said Jon Weaver, Founder and CEO of Pilot Games. “Since 2014, we’ve focused on developing original technology that helps our charitable partners succeed, while delivering exciting experiences for players. Receiving another Notice of Allowance from the USPTO is further recognition of the innovation our team continues to bring to the market.” “Protecting innovation is an important part of advancing charitable gaming,” Weaver added. “Our focus remains on creating new technologies, introducing new games, and helping charities maximize their fundraising opportunities.”

The company’s significant investment into creative research and development has resulted in one of the industry’s largest electronic pull-tab game libraries and a growing catalogue of proprietary technologies.

Earlier, Pilot was awarded U.S. Patent No. 12,367,737 relating to its innovative watermark technology for electronic pull-tab games.

Since entering the charitable gaming market in 2014, Pilot Games has become an industry leader through continuous and imaginative product creation, frequent game releases, and a commitment to serving charities with industry-leading performance.

About Pilot Games

Founded in 2014, Pilot Games develops innovative electronic pull-tab games and gaming technology for US Charitable Gaming and International State Lotteries. With a growing portfolio of patented technologies, one of the industry’s largest electronic pull-tab game libraries, and a commitment to continuous innovation, Pilot Games helps charities and lotteries increase engagement and fundraising through best-in-class electronic gaming experiences.

CONTACT: Will Reeves, Pilot Gaming Systems, Inc, wreeves@pilotgames.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pilot-games-receives-notice-of-allowance-for-second-us-patent-protecting-electronic-pull-tab-innovation-302833798.html

SOURCE Pilot Games